相关实验视频
Updated: Jan 12, 2026

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
890
关于肥胖管理的审查:饮食,运动和药物治疗
1Medicine, McGill University, Montreal, Quebec, Canada.
BMJ public health
|November 7, 2025
概括
肥胖是心脏代谢疾病的主要危险因素. 本综述探讨了管理肥胖的临床指导方针,包括改变生活方式和药物,作为治疗的分层方法.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 公共卫生 公共卫生
背景情况:
- 肥胖是北美成年人心脏代谢疾病的重要和不断增长的危险因素.
- 肥胖的日益增长需要有效的临床管理策略.
研究的目的:
- 审查当前管理超重和肥胖患者的临床指南.
- 探索分层管理策略,包括生活方式干预和药物治疗.
主要方法:
- 来自加拿大和欧洲的临床指南的审查.
- 对肥胖管理的一线和二线治疗方法的分析.
主要成果:
- 准则建议对肥胖管理采取分层方法.
- 第一线治疗包括饮食,运动和行为治疗.
- 第二线治疗包括使用抗肥胖药物.
结论:
- 目前的指导方针为医生提供了一个管理肥胖的框架.
- 改变生活方式和药物治疗的结合对于有效的肥胖治疗至关重要.
- 持续探索管理策略对于缓解肥胖的传播至关重要.
相关概念视频
Diabetes: Management and Pharmacotherapy
853
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
853
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
230
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
230
Drug Dosing: Obese Patients
208
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
208
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
163
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
163
Atherosclerosis III: Management
307
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
307
Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K

